Progress and prospects of neoadjuvant target therapy and immunotherapy for non-small cell lung cancer
-
摘要: 肺癌是全球发病率和死亡率最高的恶性肿瘤。近年来，随着新型药物的出现和治疗模式的优化，肺癌患者的预后已有一定改善。新辅助治疗是指对潜在可接受手术切除的患者，先给予术前抗肿瘤治疗后再行手术治疗。新辅助治疗通过术前治疗可以缩小肿瘤体积，降低肿瘤分期；并且可以杀灭患者机体中循环肿瘤细胞及微转移病灶，令患者远期生存获益。靶向治疗及免疫治疗已被应用于晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的一线治疗。因此，有临床试验尝试将以上两种治疗手段应用于早期可切除NSCLC患者的新辅助治疗。本文针对新辅助靶向及免疫治疗对早期可切除NSCLC患者的疗效、治疗中的潜在风险予以综述，并探讨新辅助治疗的未来发展方向。Abstract: Of all malignant tumors, lung cancer has the highest morbidity and mortality worldwide. In recent years, with the emergence of new drugs and the optimization of treatment models, the prognosis of patients with lung cancer has improved. Neoadjuvant therapy refers to the treatment provided to patients with a resectable tumor prior to surgery. This treatment can reduce tumor volume and downstage the tumor; it is also reported to remove circulating tumor cells and micrometastasis, and enable patients to achieve longer survival. Targeted therapy and immunotherapy have been used as the first-line treatment for non-small cell lung cancer (NSCLC). Some clinical trials have proposed the use of targeted therapy and immunotherapy as neoadjuvant therapy. This review intends to summarize the efficacies and potential risks of neoadjuvant targeted therapy and immunotherapy in patients with NSCLC and to discuss future developments in neoadjuvant therapy.
-
Key words:
- non-small cell lung cancer /
- neoadjuvant therapy /
- targeted therapy /
- immunotherapy
-
表 1 新辅助靶向及免疫治疗临床实验数据
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590 [2] Allen TM. Ligand-targeted therapeutics in anticancer therapy[J]. Nat Rev Cancer, 2002, 2(10):750-763. doi: 10.1038/nrc903 [3] Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC[J]. Nat Rev Clin Oncol, 2019, 16(6):341-355. doi: 10.1038/s41571-019-0173-9 [4] Wu YL, Zhang L, Kim DW, et al. Phase Ⅰb/Ⅱstudy of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non small cell lung cancer[J]. J Clin Oncol, 2018, 36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326 [5] Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers[J]. Ann Oncol, 2018, 29(8):1869-1876. doi: 10.1093/annonc/mdy137 [6] Frei E 3rd. What's in a name-neoadjuvant[J]. J Natl Cancer Inst, 1988, 80(14):1088-1089. doi: 10.1093/jnci/80.14.1088 [7] NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for nonsmallcell lung cancer:a systematic review and metaanalysis of individual participant data[J]. Lancet, 2014, 383(9928):1561-1571. doi: 10.1016/S0140-6736(13)62159-5 [8] Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable nonsmallcell lung cancers:proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1):e42-e50. doi: 10.1016/S1470-2045(13)70334-6 [9] Cascone T, Sepesi B, Lin H, et al. A Phase Ⅰ/Ⅱstudy of neoadjuvant cisplatin, docetaxel and nintedanib for resectable non-small cell lung cancer[J]. Clin Cancer Res, 2020, DOI:10.1158/1078-0432. CCR-19-4180. [10] Detterbeck FC, Socinski MA, Gralla RJ, et al. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage nonsmall cell lung cancer[J]. J Thorac Oncol, 2008, 3(1):37-45. doi: 10.1097/JTO.0b013e31815e5d9a [11] Xiong L, Li R, Sun J, et al. Erlotinib as neoadjuvant therapy in stageⅢ A (N2) EGFR mutation positive non small cell lung cancer:aprospective, single-arm, PhaseⅡstudy[J]. Oncologist, 2019, 24(2):157-164. doi: 10.1634/theoncologist.2018-0120 [12] Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR mutation positive non small cell lung cancer (EMERGING-CTONG 1103):A randomized phase Ⅱ Study[J]. J Clin Oncol, 2019, 37(25):2235-2245. doi: 10.1200/JCO.19.00075 [13] Lecia V. Sequist, Henning Willers, Michael Lanuti, et al. The ASCENT trial:A phase Ⅱ study of neoadjuvant afatinib, chemoradiation and surgery for stage Ⅲ EGFR mutation-positive NSCLC[J]. J Clin Oncol, 2018, 36(Suppl 15):8544. https://www.researchgate.net/publication/327461683_The_ASCENT_trial_A_phase_II_study_of_neoadjuvant_afatinib_chemoradiation_and_surgery_for_stage_III_EGFR_mutation-positive_NSCLC [14] Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC):Interim analysis and biomarker data from a multicenter study (LCMC3)[J]. J Clin Oncol, 2019, 37(Suppl 15):8503. http://cn.bing.com/academic/profile?id=e87ac8cb7560fe4deed37cb6f5e61928&encoded=0&v=paper_preview&mkt=zh-cn [15] Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 bockade in resectable lung cancer[J]. N Engl J Med, 2018, 378:1976-1986. doi: 10.1056/NEJMoa1716078 [16] Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC):Updated report of a phase Ⅰ study, MK3475-223[J]. J Clin Oncol, 2019, 37(Suppl 15):8534. [17] Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC):Clinical and correlative results from the NEOSTAR study[J]. J Clin Oncol, 2019, 37(Suppl 15):8504. http://cn.bing.com/academic/profile?id=faf6135fa756e78ea8825781a3ea2e0b&encoded=0&v=paper_preview&mkt=zh-cn [18] Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage Ⅲ A resectable non-small-cell lung cancer (NSCLC):A phase Ⅱ multicenter exploratory study-Final data of patients who underwent surgical assessment[J]. J Clin Oncol, 2019, 37(Suppl 15):8509. [19] Shu CA, Grigg C, Chiuzan C, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2018, 36(Suppl 15):8532. http://cn.bing.com/academic/profile?id=8a6029b7395fd0f453bfa6d9ff104fee&encoded=0&v=paper_preview&mkt=zh-cn [20] Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project:Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) ddition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1):39-51. https://www.ncbi.nlm.nih.gov/pubmed/26762738 [21] Frei E 3rd. Multidisciplinary treatment for cancer——new opportunities[J]. Int J Radiat Oncol Biol Phys, 1982, 8(5):951-952. doi: 10.1016/0360-3016(82)90108-0 [22] Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Int J Biol Sci, 2016, 12(8):1022-1031. doi: 10.7150/ijbs.15438 [23] Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. cancer discov, 2016, 6(12):1382-1399. doi: 10.1158/2159-8290.CD-16-0577 [24] Cascone T, Hamdi H, Zhang F, et al. Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer[J], 2018, 78(Suppl 13): 1719. [25] Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy[J]. J Thorac Oncol, 2012, 7(5):825-832. doi: 10.1097/JTO.0b013e318247504a [26] Cascone T, Gold KA, Swisher SG, et al. Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer[J]. Ann Thorac Surg, 2018, 105(2):418-424. doi: 10.1016/j.athoracsur.2017.08.052 [27] Liu J, O'Donnell JS, Yan J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome[J]. Oncoimmunology, 2019, 8(5):e1581530. doi: 10.1080/2162402X.2019.1581530 [28] Retseck J, Nasr A, Lin Y, et al. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma[J]. J Transl Med, 2018, 16(1):184. doi: 10.1186/s12967-018-1563-y [29] Friedman J, Moore EC, Zolkind P, et al. Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells[J]. Clin Cancer Res, 2020, DOI: 10.1158/1078-0432.CCR-19-2209. [30] Vo JL, Yang L, Kurtz SL, et al. Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis[J]. Oncoimmunology, 2015, 3(12):e968001. http://cn.bing.com/academic/profile?id=0fa466ba1ed07667055b2fb097d179a9&encoded=0&v=paper_preview&mkt=zh-cn -
点击查看大图
表(1)
计量
- 文章访问数: 74
- HTML全文浏览量: 12
- PDF下载量: 10
- 被引次数: 0
下载:
